Predictive factors and clinicopathological characteristics of outcome in poorly differentiated thyroid carcinoma: a single-institution study

Objective To elucidate the clinicopathological characteristics and prognostic factors of poorly differentiated thyroid carcinoma. Method A total of 24912 thyroid carcinoma patients admitted to the First Medical Center of Chinese People’s Liberation Army General Hospital from 2005 to 2020 were retrospectively reviewed. A total of 94 patients (39 males and 55 females, a male-female ratio of 1:1.4) fulfilled the selection criteria. Of these, 73 patients had undergone surgery. The clinical and pathological data were collected from each enrolled patient. Univariate and multivariate Cox regression analyses were performed to determine independent prognostic factors. All analyses were performed with the SPSS version 26.0 and R version 1.2.5033 in the R Studio environment. Results The specimens included 20 cases of poorly differentiated thyroid carcinoma complicated with papillary thyroid carcinoma, 17 cases complicated with follicular thyroid carcinoma, 34 cases complicated with other pathological types and 23 with a separate entity. The patient demonstrated a large age span, median age was 57 years (range 8–85 years, average 55.20 ± 15.74 years). The survival time of the 94 cases was calculated, and the mean Overall survival time was 33 (range, 1-170) months, and the mean Recurrence-free survival time was 14 (range, 1-90) months. Recurrence-free mortality is related to the age at diagnosis, extrathyroidal extension and Associated thyroid cancer (p<0.05). In contrast, overall mortality is related to the age at diagnosis, sex, extrathyroidal extension, T stage (AJCC 8th), surgery and radiation (p<0.05). Conclusion Middle-aged and elderly patients are still at high risk for poorly differentiated thyroid carcinoma. The pathologic results of poorly differentiated thyroid carcinoma are varied, and reasonable treatment has an important impact on the prognosis of poorly differentiated thyroid carcinoma.

[1]  K. Montone,et al.  Does the Presence of Capsule Influence Prognosis in Poorly-Differentiated Thyroid Carcinoma? , 2023, Human pathology.

[2]  S. Dogan,et al.  Significance of oncocytic features in poorly differentiated thyroid carcinoma — a bi-institutional experience , 2022, Virchows Archiv.

[3]  Z. Baloch,et al.  The 2022 WHO Classification of thyroid tumors: novel concepts in nomenclature and grading. , 2022, Endocrine-related cancer.

[4]  Jie Zhou,et al.  Development and validation of a nomogram model for cancer-specific survival of patients with poorly differentiated thyroid carcinoma: A SEER database analysis , 2022, Frontiers in Endocrinology.

[5]  D. Muduly,et al.  Poorly differentiated "insular" thyroid carcinoma with solitary vascular mandibular metastasis - A rare histology and management. , 2021, Oral oncology.

[6]  R. Ghossein,et al.  Poorly differentiated thyroid carcinoma. , 2020, Seminars in diagnostic pathology.

[7]  S. Basu,et al.  Sub-segmentation specific paradigms for better individualized management of poorly differentiated thyroid carcinoma: can a systematic approach be evolved? , 2020, Nuclear medicine communications.

[8]  Y. Hirose,et al.  Clinical features of poorly differentiated thyroid papillary carcinoma. , 2019, Auris, nasus, larynx.

[9]  J. Shah,et al.  Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects. , 2019, Thyroid : official journal of the American Thyroid Association.

[10]  A. Giraudet,et al.  Predictive factors of outcome in poorly differentiated thyroid carcinomas. , 2018, European journal of cancer.

[11]  W. Faquin,et al.  FNA diagnosis of poorly differentiated thyroid carcinoma. A review of the recent literature , 2017, Cytopathology : official journal of the British Society for Clinical Cytology.

[12]  E. Blackstone,et al.  Cancer of the esophagus and esophagogastric junction—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[13]  Bin Xu,et al.  Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma , 2016, Endocrine Pathology.

[14]  N. Chikhaoui,et al.  Poorly differentiated thyroid carcinoma: a retrospective clinicopathological study , 2015, The Pan African medical journal.

[15]  J. Shah,et al.  Outcomes in patients with poorly differentiated thyroid carcinoma. , 2014, The Journal of clinical endocrinology and metabolism.

[16]  K Ann McKibbon,et al.  Current status and future prospects. , 2008, Health information and libraries journal.

[17]  A. Sakamoto,et al.  Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high‐risk group of papillary and follicular carcinomas , 1983, Cancer.

[18]  Nancy D Perrier,et al.  Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2018, CA: a cancer journal for clinicians.

[19]  L. Erickson,et al.  Aggressive Variants of Papillary Thyroid Carcinoma: Hobnail, Tall Cell, Columnar, and Solid , 2018, Advances in anatomic pathology.